Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has confirmed the pricing of its earlier announced underwritten public offering of its 11,325,000 shares of common stock. For the issue of the shares with par value of $0.001 per share, the company has entered into an underwriting agreement with Piper Jaffray & Co. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares after opening at $2.23 moved to $2.26 on last trade day and at the end of the day closed at $2.26. Company price to cash ratio as 5.69. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) showed a negative weekly performance of -8.85%.
Intrexon Corp (NYSE:XON) CEO Randal Kirk purchased 243,001 shares of the company’s stock on the open market in a transaction that occurred on Thursday, March 27th. The shares were purchased at an average cost of $25.72 per share, for a total transaction of $6,249,985.72. Intrexon Corp (NYSE:XON) shares fell -4.43% in last trading session and ended the day on $22.43. XON return on equity ratio is recorded as -73.10% and its return on assets is -59.70%. Intrexon Corp (NYSE:XON) yearly performance is 357.78%.
Investors eyeing a purchase of Horizon Pharma Inc (NASDAQ:HZNP) shares, but cautious about paying the going market price of $14.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $10 strike, which has a bid at the time of this writing of $1.20. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -4.39% in last trading session and was closed at $13.51, while trading in range of $13.14 – 14.51. Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 77.30%.
Pacific Biosciences of California, Inc, (PACB) provider of the PacBio (R) RS II, announced the release of a software upgrade for its Single Molecule, Real-Time (SMRT(R)) DNA Sequencing platform. SMRT Analysis 2.2 provides enhanced functionality to support two additional applications that uniquely benefit from the company’s long-read sequencing technology: Iso-Seq(TM) full-length transcript/isoform sequencing, and human leukocyte antigen (HLA) haplotype phasing. Pacific Biosciences of California (NASDAQ:PACB) weekly performance is -9.53%. On last trading day company shares ended up $4.84. Pacific Biosciences of California (NASDAQ:PACB) distance from 50-day simple moving average (SMA50) is -24.21%. Analysts mean target price for the company is $8.00.
Leave a Reply